Synovus Financial’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Synovus Financial’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-333	Closed	-$1K	–	2272
2020 Q1	$1K	Hold	333	–	–	﹤0.01%	2117
2019 Q4	$2K	Hold	333	–	–	﹤0.01%	1451
2019 Q3	$2K	Hold	333	–	–	﹤0.01%	1407
2019 Q2	$2K	Hold	333	–	–	﹤0.01%	1334
2019 Q1	$2K	Hold	333	–	–	﹤0.01%	1371
2018 Q4	$1K	Hold	333	–	–	﹤0.01%	1382
2018 Q3	$2K	Buy	+333	New	+$2.56K	﹤0.01%	1346

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Synovus Financial's PGNX Position: Q2 2020 in Review

Synovus Financial sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 333 shares — an estimated $1K sold.

Synovus Financial first reported a position in PGNX in Q3 2018 and held it in 7 quarters. The position peaked at $2K in Q4 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Synovus Financial reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Synovus Financial sold 333 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $1K.
Synovus Financial first reported a position in Progenics Pharmaceuticals Inc in Q3 2018 and held it in 7 quarters.
Synovus Financial's Progenics Pharmaceuticals Inc position peaked at $2K in Q4 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Synovus Financial's 13F filing for Q2 2020, filed 10 Aug 2020.